Literature DB >> 9106620

Probing interactions between viral DNA and human immunodeficiency virus type 1 integrase using dinucleotides.

A Mazumder1, H Uchida, N Neamati, S Sunder, M Jaworska-Maslanka, E Wickstrom, F Zeng, R A Jones, R F Mandes, H K Chenault, Y Pommier.   

Abstract

Retroviral integrases are essential for viral replication and represent an attractive chemotherapeutic target. In the current study, we demonstrated the activity of micromolar concentrations of dinucleotides against human immunodeficiency virus type 1 (HIV-1), HIV type 2 (HIV-2), simian immunodeficiency virus, and feline immunodeficiency virus integrases. The structure-activity relationship indicates that 5'-phosphorylation enhances potency and that phosphodiester and sugar modifications affect the inhibition of HIV-1 integrase. Base sequence selectivity was observed: pAC, pAT, and pCT were the most potent inhibitors, whereas pAA, pGA, and pGC showed low activity at 100 microM. The inhibition by pAC is consistent with the interaction of the enzyme with the 5' end of the noncleaved strand (5'-AC-3'). The linear and cyclic dinucleotides released by the 3'-processing reaction did not affect enzymatic activity at physiological concentrations. An increase in the length to trinucleotides or tetranucleotides enhanced potency by only 2-3-fold, suggesting that two neighboring bases may be sufficient for significant interactions. Inhibition of a truncated (50-212) integrase mutant and global inhibition of all nucleophiles in the 3'-processing reaction suggest that dinucleotides bind in the catalytic core. All of the active dinucleotides inhibited enzyme/DNA binding in their respective IC50 range. Although the dinucleotides tested showed no antiviral activity, these observations demonstrate the usefulness of dinucleotides in elucidating enzyme mechanisms and as potential ligands for cocrystallization and as lead structures for development of antivirals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106620     DOI: 10.1124/mol.51.4.567

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent.

Authors:  Vasu Nair; Guochen Chi; Roger Ptak; Nouri Neamati
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

2.  Identification of a nucleotide binding site in HIV-1 integrase.

Authors:  R R Drake; N Neamati; H Hong; A A Pilon; P Sunthankar; S D Hume; G W Milne; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

3.  A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HIV integrase and anti-HIV activity.

Authors:  Guochen Chi; Vasu Nair; Elena Semenova; Yves Pommier
Journal:  Bioorg Med Chem Lett       Date:  2006-12-15       Impact factor: 2.823

4.  Localization of ASV integrase-DNA contacts by site-directed crosslinking and their structural analysis.

Authors:  Elena Peletskaya; Mark Andrake; Alla Gustchina; George Merkel; Jerry Alexandratos; Dongwen Zhou; Ravi S Bojja; Tadashi Satoh; Mikhail Potapov; Alex Kogon; Viktor Potapov; Alexander Wlodawer; Anna Marie Skalka
Journal:  PLoS One       Date:  2011-12-01       Impact factor: 3.240

Review 5.  Different Pathways Leading to Integrase Inhibitors Resistance.

Authors:  Eloïse Thierry; Eric Deprez; Olivier Delelis
Journal:  Front Microbiol       Date:  2017-01-11       Impact factor: 5.640

Review 6.  Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids.

Authors:  Vasu Nair; Maurice Okello
Journal:  Molecules       Date:  2015-07-13       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.